SCHEMBL1234904

SCHEMBL1234904

CCOc1ccc(-c2cc3ncn(C)c(=O)c3c(NC3CC3)n2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1235841 0.90 SYK (1.00) SYK
SCHEMBL1057612 0.85 SYK (0.79) SYK
SCHEMBL1235537 0.84 SYK (1.00) SYK
SCHEMBL1235538 0.84 SYK (0.83) SYK
SCHEMBL1235068 0.84 SYK (1.00) SYK
SCHEMBL1058132 0.83 SYK (0.79) SYK
SCHEMBL1234952 0.82 SYK (1.00) SYK
SCHEMBL1234054 0.82 SYK (1.00) SYK
SCHEMBL1234946 0.82 SYK (1.00) SYK
SCHEMBL1236206 0.82 SYK (1.00) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722692-B2 Compounds and compositions as Syk kinase inhibitors IRM LLC (BM) 2014-05-13 US claimed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US claimed
EP-2459558-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
WO-2011014795-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
US-8722692-B2 Compounds and compositions as Syk kinase inhibitors IRM LLC (BM) 2014-05-13 US disclosed
US-8722692-B2 Compounds and compositions as Syk kinase inhibitors IRM LLC (BM) 2014-05-13 US disclosed
US-8722692-B2 Compounds and compositions as Syk kinase inhibitors IRM LLC (BM) 2014-05-13 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
EP-2459558-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
WO-2011014795-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014795-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.